• 2017 Oct, Featured Member of the month: APS





     
     
    Contact Information:
    Scott Barnhill,
    AS, SRS, RLATG
    Business Development Executive 
    American Preclinical Services, LLC
    8945 Evergreen Blvd.
    Minneapolis, MN 55433
    Main Phone:
    763-717-7990
    Direct Phone:
    763-951-8990
    Mobile:
    858-822-9648
    Direct Fax:
    763-951-8991
    sbarnhill@apsemail.com
    americanpreclinical.com

    The APS Preclinical Program:
    Your Path to Success 
     
    Finding a reliable partner in the preclinical CRO space can be challenging. In the early stages of product development, having a partner you can trust and rely on is of paramount importance.
    Welcome to American Preclinical Services. APS is an AAALAC and ISO17025 accredited, USDA registered and GLP compliant preclinical center of excellence located in Minneapolis, MN.

    At APS, we have developed a comprehensive Powerful Preclinical Program to assist companies in meeting their R&D goals. The APS Preclinical Program includes regulatory, biocompatibility, interventional medical device, surgical medical device, analytical, physician training, bioskills, pathology, pharmacology, and toxicology services. With this breadth of services under one roof, APS can advance your programs in all aspects of your product’s preclinical requirements. APS is adept at tailoring a Preclinical Program to fit your goals, with you and your team having direct collaborative control over study conduct and reporting timelines.
    Over 150 employees strong, the staff at APS have the scientific and technical expertise to guide your team in today’s fast paced and ever changing regulatory environment.  Whether you are conducting pilot evaluations, feasibility testing, or GLP studies, you will have industry experts to rely on every step of the way.
     

  • FBB october 2017 Newsletter






     
                 
                   
     
    Our newsletter keeps you in the loop of FBB’s News & Events. If for any reason you would like to  
    You are welcome to join us again at a later time
     
    BECOME A

     

     
    Thank You to our  Partners
     
     

    http://www.analytics-ventures.com/
     
     
     
     
     
     
     
     
     
     
     
     

     

    Big Thank You to our Sponsors & Members
     

     
     
     
     
     
     
     
     
     
     
     
     
     

     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     


     
    French BioBeach October 2017 Newsletter
     
    Dear French BioBeach community, 
     
    We have some great news for you… The FBB breakfast IS BACK! Thanks to our sponsor Antibody Design Labs you will have the opportunity to start this coming Tuesday with a delicious coffee and croissant :)
     
    This newsletter start with our FBB events. Our networking opportunities with our Breakfast and traditional Happy Hour rendez-vous.
     
    Then, our partner APL (American Preclinical Services) will be presented in the “Company of the Month” section. You will also find a link to apply for a Connected Intelligence Executive Circle organized by CLC.
     
    We end this exciting newsletter by some events and news we thought you might enjoy.
     
    Thanks to your support, we continue to monitor what happens in the Life Sciences community fostering new Partnering and Business Opportunities.
     
    The French BioBeach Team  Cool
     
    Upcoming French BioBeach Events
     
     
    Coffee & Croissants
     
    The FBB breakfast is back!!! :D
       
    What’s best than a coffee and a croissant to start your tuesday properly?
        

    When? Tuesday October 3rd at 8:00am

     

    Where?  Antibody Design Labs
    Meeting in Coat-9, Conference center Union Station  –> Conference Room located next to “Come On In Cafe” @ 11120 Roselle St., Suite J San Diego, CA 92121

     

     Look for the French Flag…

     
     
     
     
     
     
     
     
     
    Monthly Happy Hour @ Bella Vista
     

    End of the week, Sunset & Happy Hour After Work? Join us for our Monthly (exeptionnaly the 3rd Friday of this month) Networking Happy Hours. 
     
    We look forward to seeing you there…!


    When? Friday, October 20th, from 5:00 to 7:00pm

     

    Where?  Bella Vista Social Club & Caffe, 2880 Torrey Pines Scenic Dr, La Jolla, CA 92037 

    Look for our French BioBeach sign!

     

     
     
     
     
     
    Free (no host bar)
    & open to all
     
     

     
     
     
    or just show up :)

    Whether you would like to come debrief recent events or come discuss your latest startup project, the needs of your company (funding, advisors, people, CRO, IP attorney …), your latest scientific discovery (that you have of course already covered by a provisional), or just grab a TGIF drink and a glimpse of the sunset over the ocean with a bunch of international men & women of the San Diego biotech community, come join us at Bella V. .. and don’t worry, you don’t have to be French or speak French …

    Cheers 

     
     
    Company of the Month
     
     
    The APS Preclinical Program: Your Path to Success

    Finding a reliable partner in the preclinical CRO space can be challenging. In the early stages of product development, having a partner you can trust and rely on is of paramount importance.
    Welcome to American Preclinical Services. APS is an AAALAC and ISO17025 accredited, USDA registered and GLP compliant preclinical center of excellence located in Minneapolis, MN.
    At APS, we have developed a comprehensive Powerful Preclinical Program to assist companies in meeting their R&D goals. The APS Preclinical Program includes regulatory, biocompatibility, interventional medical device, surgical medical device, analytical, physician training, bioskills, pathology, pharmacology, and toxicology services. 
     
    With this breadth of services under one roof, APS can advance your programs in all aspects of your product’s preclinical requirements. APS is adept at tailoring a Preclinical Program to fit your goals, with you and your team having direct collaborative control over study conduct and reporting timelines.

    Over 150 employees strong, the staff at APS have the scientific and technical expertise to guide your team in today’s fast paced and ever changing regulatory environment.  Whether you are conducting pilot evaluations, feasibility testing, or GLP studies, you will have industry experts to rely on every step of the way.
      
     
    Contact Information:
    Scott Barnhill, AS, SRS, RLATG 
    Business Development Executive 
    American Preclinical Services, LLC
    8945 Evergreen Blvd | Minneapolis, MN 55433
    Main Phone: 763-717-7990 | Direct Phone: 763-951-8990 | Mobile: 858-822-9648
    Direct Fax: 763-951-8991
    sbarnhill@apsemail.com
     
     
     
    Events
     
     
     
    CLC : 

    Connected Intelligence Executive Circle (SM)


    A virtual group coaching and networking experience like no other. By invitation or recommendation only


    All participants are sharp, supportive and interesting executives like you. Participants join each session via video conferencing from anywhere in the world, from any device, via private Zoom platform. 

    When?   Strating in October
     
    Where? video conferencing
     

    Confédération des Associations Centraliennes et Supelec
    Alumni Days Centrale(s) et Supélec 2017 à San Diego

    When? Thursday, July 20 2017 |

    4:00 pm – 7:00pm
    Where? Farmer & the Seahorse |
    10996 Torreyana Rd |
    San Diego, California 92121



     

                                                                                                             
     

    Charles River Presents : An Integrated Approach to Assess Drug-Induced Cardiovascular Liabilities

    Can we improve translation of preclinical data to clinical outcomes?


    Early in the drug development lifecycle, the process of evaluating compounds for hemodynamic and electrophysiological cardiovascular risk does not follow a regulated guideline, but more of an investigational method. Determining in-vitro assessments that translate to the whole animal and more importantly to the clinical outcome is paramount…

    When? 

    October 25, 2017 | 11:00 AM – 2:00 PM

     



    Where? 

    Green Acre | Campus Pointe 10300 Campus Point Drive | San Diego, CA 92121 Salon A


                                           
     
    In the News
     
     
    •  Drug from Sanford Burnham Prebys enters testing

     
     
     
    • International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and Future Clinical Trials

       

     
     
     
    LaughingThank you for reading!!         
     
     
    French BioBeach
    Ph: +1 (858) 215-2462 • www.frenchbiobeach.com

            

  • Biocom in France: Part Deux

    Franco-American biotech ties flourish

    By Joe Panetta11:55 A.M.MAY 4, 2015

    panettaimage1a_r620x349

     

     

     

     

     

     

    San Diego delegation and PACA partners outside the offices of Innate Pharma. — Biocom

    (Editor's note: This is Part 2 of Biocom CEO Joe Panetta's return trip to southeastern France with a delegation from Biocom and French BioBeach, to strengthen the partnership between the region and Southern California. You can read Part 1 of the trip to Provence-Alpes-Côte d'Azur, or PACA, here)

    For two days since arriving here in Marseille to continue our Biocom and French BioBeach delegation trip, we have been awed by the growth of this life science cluster within the second largest city in France. We have visited clinical research hospitals and life science parks, an incubator and biotech companies including one that has been quite successful, as well as met with regional political and business leaders and potential partners.

    It has been a whirlwind two days in which our hosts and Biocom partners - Eurobiomed and the South Bio Alliance – have gone to extraordinary lengths to extend their hospitality and a unique perspective on all that this region can offer in the life sciences arena.

    We began yesterday with a visit to the Luminy campus of Marseille Immunopol, the subcluster for immunology in Marseille. It has unique positioning for immunology as a key technology here and has created an alliance that brings together all of its stakeholders within a collaborative ecosystem for innovation in immunology. The Immunopole includes hospitals, research institutes, academic labs and biotech companies.

    Marseille has a 40-year history of discovery and development in immunology beginning with Beckman Coulter Innotec which led to 60 spin-offs and other start-ups such as Innate Pharma, now a very successful company that we visited within the Immunopole. Innate has raised $185 million and has completed $1.8 billion in deals since 2006 including its most recent with AstraZeneca worth $250 million in initial payment with milestones worth up to $1.3 billion.

    A second company that we talked to was HalioDx, a spin-off of Qiagen Marseille that has a unique biomarker portfolio for use potentially by large pharma in developing companion diagnostics.

    Also within the Luminy Park is the Association Grand Luminy, the sole biotech incubator in the south of France which has operated since 1985. It has 2 missions: to sustain the local economy and to create and grow companies. Since 2009 Grand Luminy has also run a Biotech Nursery to host start ups from the incubator within a structure that includes support services, an entrepreneurship manager, strategic partnership development, patenting, communications management and corporate identity.

    To obtain a better understanding of the ability of the Marseille cluster to conduct clinical trials we visited AP-HM, the 3rd largest university hospital in France built on the concept of combining a high-technology hospital with research training. The hospital is now running more than 300 clinical trials.

    The day ended with expert presentations on human resources management, drug regulation in France and company financing at the 400-year old Palais de la Bourse, which is now home to our hosts for the afternoon and evening, the International Chamber of commerce of Marseille.

    The leaders of the Regional Council, Stephane Richard of French BioBeach and I exchanged greetings and addressed guests representing life science companies, the media and business leaders followed by a networking event held to welcome our delegation. While the event lasted well into the evening we knew that we could not end the day in this great city without once again sampling the remarkable bouillabaisse that is so expertly prepared within a few great establishments here, and at 10 PM in the evening we descended upon Le Rhul Restaurant. By midnight we were satiated and exhausted, and returned to our hotel.

    Today's schedule began even earlier in the morning with a visit to the IPC Paoli Calmettes cancer treatment center. It is one of a group of cancer treatment and research centers created by the great French President Charles de Gaulle after World War II, of which there are 20 in France.

    IPC Paoli is unique in that it includes a new unit called IPC Drug Discovery which works primarily in technologies that can detect blood levels of antibodies in an attempt to better identify weaknesses of cancer cells and DNA repair mechanisms. It also has a strong epigenetics group and a group working on metastasis. The unit is trying to find partners in pharma and biotech to conduct Phase I trials and to establish start up companies.

    Investment funding is available in Marseille as we learned in a presentation on PACA Investissmente, which sponsors a capital investment fund of 19.45 million Euro,managed by Thurenne Capital. Since its first investment in 2011, it has made investments in 38 companies and created 32 partnerships in the PACA region. To apply for funding a company must be early stage and incorporated in the region.

    This trip would not have been complete without a visit to NeuroService, a contract research firm located outside Marseille in Aix-en-Provence. The company has ties to San Diego as the region's first Biocom member firm here, and does 60 percent of its business in the US. NeuroService specializes in pharmacological assays based on electrophysiological recordings of acute brain and spinal cord slices, and cultured neurons to support early phases of CNS and pain R&D programs.

    Our second long day in the region ended with an informative tour of Aix-en-Provence city center and a farewell dinner with our most cordial hosts. It has been a truly incredible visit here from the standpoint of experiencing just how similar this area is to San Diego in its life science collaboration, diversity and innovation.

    A two-year gap in visiting our partners here perhaps provided a better perspective on their progress, but we talked over dinner about the opportunity to work together more closely in the future as the bridge we are building attracts more traffic.

    SOURCE: UT SAN DIEGO

  • French biotech: A return visit

    Biocom delegation travels to southeastern France for biotech

    By Joe Panetta12:05 P.M.

    Officials of San Diego's Biocom and Eurobiomed, an agency in southeastern Francce, sign an agreement to help biotech companies do business in each other's regions. From left, Magda Marquet, founder of Althea Technologies and chair of Biocom; Jacquie Berthe, president of Eurobiomed and a scientific director of Sanofi-Aventis; and Joe Panetta, president and CEO of Biocom.

    (Editor's note: Biocom, the San Diego-based life science trade group, has long cultivated ties with biotech in other nations. Biocom CEO Joe Panetta describes the group's latest mission, a return trip to France.)

    Two years ago I reported to U-T San Diego readers on the first trip by Biocom, French BioBeach and our members to Nice and Marseilles to explore partnership opportunities between life science clusters in the two regions of southern California and the Cotes d'Azur/Provence. That visit was eye-opening for all of us who participated, as we gained a great appreciation for the entrepreneurial environment and the long history of life science company formation and success, as well as the standout experience here is the conduct of clinical trials for oncology products.

    The relationship was furthered last year as representatives of both regions including Biocom, French BioBeach, and what is now known as the Provence-Alpes-Cote d'Azur South Bioalliance

    signed a formal partnership agreement during the BIO 2014 convention in San Diego.

    We returned to Nice and Marseilles in the spirit of our formal partnership this week with some past participants from San Diego, including Biocom Board Member and lead patent counsel at WSGR, Jeffrey Guise, Mike Honeysett of Acea and me, as well as new delegates such as the CEOs of Flow Paradigm, OncioMed, Abreos Biosciences (with one of his scientists) and CVAC Systems – a very inquisitive and engaged group who have asked probing questions of our hosts here while thus far expressing enthusiasm about what we have seen on the first part of our trip in Nice.

    Here's an update on the state of life science in this region in 2015 to provide a bit of perspective and comparison with southern California.

    The industry here is represented by 400 companies employing 10,000 people. Leading companies here include Beckman Coulter, Galderma, Sanofi-Aventis and Nicox. It is France's second largest center for clinical trials with 30,000 doctors and 39,000 hospital beds. It is a center of convergence of biotechnology, aquatic technologies, IT and wireless communications and tourism, and it has 6 universities including the largest in France in Marseilles (if this all sounds familiar it is because it is a mirror image of San Diego).

    Two years ago I reported that what struck me most about this region is its advanced experience in the field of clinical medicine. This was reinforced yesterday on our visits to the Centre Antoine Lacassagne, a regional cancer center that is close to completing a synchro-cyclotron proton therapy device that is the first of its kind in Europe, and to the national Alzheimer's pilot Institut Claude Pompidou for a presentation of some leading research projects of non-drug therapies to enhance cognitive function in patients through the use of IT-based solutions.

    The device at Lacassagne is one-fourth the weight of previous devices and uses 1/8 the electricity with a new dose administration technology called PBS – pencil beam scanning which is intensity- modulated to provide much higher "conformation" to tumor shape than past devices.

    We followed up with presentations by lead scientific researchers at the Institute of Biology Valrose within the University of Nice Sophia Antipolis, an international research center that addresses fundamental topics in developmental biology with links to associated diseases such as cancer, diabetes and obesity and utilizing various scientific approaches such as genetics, cell signaling and integrative physiology carried out on a wide range of model organisms.

    The impressive presentations on human adipose stem cells and obesity, on generation of functional beta cells from alternative pancreatic cell subtypes, on a flow cytometry iBV platform and on experimental histology in development and disease drew comments and questions by our group regarding the competitive nature of the work with what is being done in San Diego.

    Our long day ended with all of our companies making quick pitch presentations to an invited group of Nice life science company representatives at the Team Cote d'Azur office.

    Today (Tuesday) began with a legal presentation on doing business in France by the FIDAL law group ( the most popular question being whether it is actually possible to terminate an employee in France) followed by a day of visits to some of Nice's leading life science companies.

    Two that were of particular relevance to our San Diego group were Integra Life which is a device company based in New Jersey and producing brain catherization and mapping products here, and TxCell which is developing T cell immunotherapies for severe chronic inflammatory and autoimmune diseases such as Crohn's Disease. The latter drew questions from the entire group because the technology was an area of familiarity to many of our participants but even more so because all agreed that the research rivaled what they had seen in immunotherapy product development in San Diego.

    Another long day ended with our transfer to Marseilles and a late-evening reception hosted by the Eurbiomed-Provence Promotion Team. We'll spend the next two days here in Marseilles further examining the many potential opportunities for our southern California companies.

    SOURCE: UT SAN DIEGO

  • Biocom Annual Dinner Makes Waves | Innovation Night @ La Jolla Playhouse

    December Events FBB Attended

     

    Communique by Biocom on their annual dinner

    Sold-Out Biocom Annual Dinner Makes Waves

    The 2014 Biocom Annual Dinner, “Making Waves”, was definitely one for the ages. Many attendees of the sold-out event came away saying the program this year was one of the strongest ever. We thankall our sponsors for making this evening possible, especially Lead Sponsors BioMed Realty and VWR.

    The evening started with the popular networking reception, where old friendships were renewed and new relationships born. Retiring to the ballroom, the evening started off by a hearty greeting by Biocom Board Chair Magda Marquet and Biocom President and CEO Joe Panetta, followed by a “selfie” of the audience from the podium (available on Biocom’s Facebook page).

    City of San Diego Mayor Kevin Faulconer welcomed attendees and emphasized the importance of the life sciences to the region’s economy and to him personally. Congressman Scott Peters was then awarded Biocom’s “Elected Official of the Year,” becoming one of a very few policy makers who have won the award more than once. Due to votes in Washington DC, Congressman Peters accepted the award via video.

    Stephanie Venn-Watson, Director of the Translational Medicine and Research Program of the National Marine Mammal Foundation, described that organization’s work in Point Loma using dolphins in diabetes research. Dr. Venn-Watson pointed out that for purposes of diabetes research, dolphins are actually more similar to humans than rats or other mammals. Among its most exciting findings so far:dolphins have an “off switch” for some types of diabetes, giving hope that this research will lead to a similar finding in humans.

    The first portion of the evening closed with one of the most moving, powerful patient presentations ever given on a Biocom stage, as Sarah Wilson talked about her family’s challenges with two young children with Type I diabetes. She described the family’s specially trained dog, Ruby, who can detect dangerously low and high blood sugar by scent, and how Ruby likely saved her daughter’s life on the very first day of service by alerting the Wilsons to dangerous fluctuations in glucose readings overnight. And also how, after re-training the dog to track two members of the family, they realized this was aging the dog pre-maturely, and so now Sarah again wakes up every two hours during the night to test their blood sugars to give the dog recuperation time, lest they lose this valuable member of their team. Few who heard this family’s story will forget it.

    The keynote speaker was Dr. Rudy Tanzi, one of the world’s foremost Alzheimer’s researchers. Dr. Tanzi described how we got to where we currently are in our knowledge of Alzheimer’s: how it is believed that damage may start 15 years before any outward symptoms appear; the relationship between amyloid plaques, tangles, and manifestation of alzheimer’s, and the key and recurring role San Diego researchers and companies have played in advancing this knowledge.

    Dr. Tanzi talked about the difficulty in how Alzheimer’s has traditionally been modeled in animals (specifically, mice), in that it was not leading to discoveries that would effectively treat the disease. He hopes this will change with his team’s announcement last month that they had developed a method to create “Alzheimer’s in a dish,” human brain cells which manifest Alzheimer’s. This was accomplished by placing the cells in a gel, where they could develop neural networks similar to those found in the human brain. For the first time, researchers will be able to work with living human cells afflicted with Alzheimer’s. It is greatly hoped this breakthrough will accelerate research and effective treatments for Alzheimer’s. If a therapeutic cocktail can stop tangle development and the brain inflammation which is known to accompany Alzheimer’s development by “turning off” a physiological switch, it is hoped that an effective treatment for Alzheimer’s is possible.

    “Rock Star of Science,” Dr. Tanzi is also a passionate musician who has performed with Joe Perry of Aerosmith, among others. He closed his presentation by playing “Remember Me,” a beautiful, haunting song he wrote with Chris Mann, finalist on NBC’s “The Voice,” whose father is afflicted with Alzheimer’s. It is hoped this song will become an anthem to raise awareness about Alzheimer’s and give a voice to those patients and their loved ones. It will be in official release soon, we will keep you posted when it is available.

    Pictures from the event will be posted in the coming days on the Biocom Facebook page (please “like” us so you will see these in your facebook feed). Thank you to our members and their guests for sharing this most special of evenings with us, and to our sponsors for making it possible.

    The Wilson family visited Biocom member Dexcom, which makes some of the devices the children use.

    Biocom Board Chair Magda Marquet and Biocom President and CEO Joe Panetta

    San Diego Mayor Kevin Faulconer welcomes guests

    Congressman Scott Peters Accepts the Biocom 2014 Elected Official of the Year Award via video

    Charles McWilliams of VWR

    Stephanie Venn-Watson of the National Marine Mammal Foundation

    Patient Advocate Sarah Wilson speaks about the challenges of raising two Type I diabetic children

    R. Kent Griffin, Jr. of BioMed Realty Trust

    Keynote speaker Dr. Rudolph Tanzi

     

    SOURCE: BIOCOM

  • Curtana pharmaceuticals awarded NIH small business technology transfer grant to advance glioblastoma cancer therapy

    Curtana pharmaceuticals awarded NIH small business technology transfer grant to adavance glioblastoma cancer therapy

    CURTANA PHARMACEUTICALS AWARDED NIH SMALL BUSINESS TECHNOLOGY TRANSFER GRANT TO ADVANCE GLIOBLASTOMA CANCER THERAPYCURTANA PHARMACEUTICALS AWARDED NIH SMALL BUSINESS TECHNOLOGY TRANSFER GRANT TO ADVANCE GLIOBLASTOMA CANCER THERAPYCurtana Pharmaceuticals, a privately-held, preclinical stage pharmaceutical company developing the first targeted small molecule therapeutics for glioblastoma (GBM) and other brain cancers, announced today that it has been awarded $225,000 by the National Cancer Institute of the National Institutes of Health (NIH) through the Small Business Technology Transfer (STTR) program.  The STTR grant follows closely on the heels of a $7.6 million product development grant funded by the Cancer Prevention and Research Institute of Texas (CPRIT). Collaborating with Curtana on the STTR grant as Principal Investigator is Professor Santosh Kesari, Director of Neuro-Oncology at Moores Cancer Center, University of California, San Diego and co-founder of Curtana whose research, utilizing a novel combined pharmacophore-based small molecule design methodology, has discovered several candidate compounds.The joint project will involve important in vivo pre-clinical studies designed to validate the efficacy of a small molecule inhibitor of OLIG2 function in GBM.  Typically, OLIG2 is not active in normal brain tissue and is not found in normal tissues outside the central nervous system.  However, it is highly expressed in all diffuse gliomas and nearly 100% of glioma cancer stem cells (CSCs) that are positive for the CD133 stem cell marker.  The relevance for therapy derives from the finding that over-expression of OLIG2 drives turmorigenesis and promotes resistance to chemotherapy and radiation therapy.“The STTR grant award reinforces the promise of our technology platform and approach to treating glioblastoma,” stated Gregory Stein, M.D., M.B.A., Chief Executive Officer, Curtana Pharmaceuticals.  “Both the financial support of the NIH grant and the collaboration with Dr. Kesari and his team, a prominent cancer research group, will accelerate the development of our therapy for brain cancer patients who currently have limited therapeutic options.”Current treatments have evolved little over the last two decades for GBM, which has a median survival of less than 15-months and a five-year survival rate of less than 10%.  GBM is the most common and most aggressive of the malignant primary brain tumors in adults and one of a group of tumors referred to as gliomas.  Incidence in the U.S. is approximately 10,000 cases per year.  Conventional therapeutic approaches for GBM often include surgery, chemotherapy and radiation, which target the tumor bulk, but have limited effect on the cancer stem cells (CSCs) that drive tumor growth and recurrence.About Curtana Pharmaceuticals

    Curtana Pharmaceuticals, founded in 2013, is a privately-held, preclinical-stage pharmaceutical company currently headquartered in San Diego, California.  The company focuses on the development of novel, first-in-class, small molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma and other cancers.  Curtana’s OLIG2 inhibitors will be the only adjuvant treatment for nearly all gliomas, including high-grade glioblastomas, which specifically targets the cancer stem cells and is a potent radiosensitizer.  For more information, visit www.curtanapharma.com.  The grant reported in this press release was supported by the National Cancer Institute of the National Institutes of Health under Award Number R1CA186435.  The grant will finance 100% of the proposed project.

    Disclaimer

    The content of this release is solely the representation of Curtana Pharmaceuticals and does not necessarily represent the official views of the National Institutes of Health.

     

    This press release source is PR Buzz.

  • 2014 BIOCOM/French BioBeach’s Trade Delegation to France

     CLICK ON THE IMAGE TO OPEN THE PDF [CLICKABLE LINKS]. 

     SPACE IS LIMITED, REGISTER TODAY!

    2nd edition US trade delegation to France Sept/Oct 2014

    2nd edition US trade delegation to France Sept/Oct 2014

     

  • TxCell raises €16M on the French stock exchange

    logo-txcell

    The fund raising by the Sophia Antipolis-based biotech company will enable it to market its treatment for Crohn’s disease

     

    TxCell, with its head office in Sophia Antipolis, has just announced that it has raised €16.2M after its floatation on  the French stock exchange.

    The company, specializing in immunotherapy for the treatment of chronic inflammatory auto-immune diseases, was supported by the company’s key shareholders, Auriga Partners, Seventure and Innobio and by Bpifrance Participations who subscribed to the capital increase for the amounts of €5.7M and €8.1M respectively.

    TxCell makes this type of innovative cell therapy economically viable for the first time. Using the patient’s own cells it treats chronic and severe inflammatory and auto-immune diseases. “TxCell’s listing on Euronext in Paris is a major step in accelerating the company’s development and its next-generation cell-therapies”, confirmedDamian Marron, the company’s Chief Executive Officer, in a press release.

    This new type of treatment could “change the life of thousands of refractory patients suffering from inflammatory auto-immune diseases such as Crohn’s disease” he added.

    Source:  Team Cote d’Azur

  • OZ Biosciences now in the USA

    ozb inc2

    ozb inc2

    Due to the rising success of our transfection products, OZ Biosciences is now opening its US office in San Diego, CA.

    It is an exciting opportunity for OZ Biosciences to expand its worldwide representation that will enable our North American customers to benefit from a new level of services through OZ Biosciences Inc.

    Customers in America can directly order through OZ Biosciences Inc.
    The US team at our new office location will be pleased to serve you with the quality and service you can expect.

    OZ Biosciences Inc
    4901 Morena Blvd Suite 501
    San Diego CA 92117
    Tel: +1-858-246-7840
    Fax: +1-855-631-0626

    Contact: contactUSA@ozbiosciences.com
    Technical Question : techUSA@ozbiosciences.com
    Order : orderUSA@ozbiosciences.com

    www.ozbiosciences.com

    2012_0321_Proud_Member_Of_FrenchBioBeach

    OZ Biosciences SAS FRANCE
    Parc Scientifique de Luminy, case 922, 13288 Marseille Cedex 9, France
    Customer Service: +33 (0) 486 948 516, contact@ozbiosciences.com
    Technical Service: tech@ozbiosciences.com – Fax: +33 (0) 486 948 515
    For more information, visit us at ozbiosciences.com

  • Why organize a French-American biotech network in San Diego?

    French Bio-Beach gathers three different communities:

    * The San Diego biotech community

    * The French biotech community

    * French scientists working in the San Diego area

     

    Through French Bio-Beach, all three communities stand to benefit from a tighter collaboration:

    * Increased international visibility to investors and entrepreneurs for the San Diego biotech community

    * Access to sources of capital and exposure to a proven biotech start-up climate for French biotech companies

    * Helping French scientists find job opportunities back at home or in San Diego